HLN — Haleon plc stock price, charts and financials

NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·UK

Latest market price

9.93

-0.11-1.05%

Overview Short InterestFilings

HLNQT51Haleon plc·NYSE

Overview Short InterestFilings

9.93-1.05%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

TEVA-0.17%$35.30 TAK+0.46%$17.53 VTRS-0.94%$16.27 ELAN+0.70%$22.27 RDY-1.19%$12.07 LNTH-0.11%$100.84 AMRX-1.16%$17.93 INDV-1.31%$38.31

Snapshot

Index	-	P/E	19.90	EPS (ttm)	0.50	Insider Own	-	Shs Outstand	4.40B	Perf Week	1.62%

Market Cap	43.90B	Forward P/E	16.27	EPS next Y	0.62	Insider Trans	-	Shs Float	4.43B	Perf Month	3.30%

Enterprise Value	53.69B	PEG	1.06	EPS next Q	-	Inst Own	12.68%	Short Float	0.29%	Perf Quarter	7.85%

Income	2.21B	P/S	2.95	EPS this Y	-7.67%	Inst Trans	-	Short Ratio	1.41	Perf Half Y	-7.64%

Sales	14.88B	P/B	2.02	EPS next Y	9.43%	ROA	5.11%	Short Interest	12.63M	Perf YTD	-0.79%

Book/sh	-	P/C	21.99	EPS next 5Y	7.88%	ROE	10.30%	52W High	11.16 -11.08%	Perf Year	8.43%

Cash/sh	-	P/FCF	27.48	EPS past 3/5Y	17.12% 9.07%	ROIC	6.60%	52W Low	8.56 15.95%	Perf 3Y	20.55%

Dividend Est.	0.13 (1.29%)	EV/EBITDA	14.20	Sales past 3/5Y	2.85% 2.79%	Gross Margin	64.77%	Volatility	1.80% 1.71%	Perf 5Y	-

Dividend TTM	0.06 (0.60%)	EV/Sales	3.61	EPS Y/Y TTM	49.18%	Oper. Margin	21.87%	ATR (14)	0.21	Perf 10Y	-

Dividend Ex-Date	Aug 14, 2026	Quick Ratio	0.71	Sales Y/Y TTM	26.11%	Profit Margin	15.11%	RSI (14)	57.04	Recom	2.25

Dividend Gr. 3/5Y	-	Current Ratio	0.92	EPS Q/Q	-49.67%	SMA20	0.86%	Beta	-0.06	Target Price	10.20

Payout	36.71%	Debt/Eq	0.52	Sales Q/Q	103.02%	SMA50	5.61%	Rel Volume	0.55	Prev Close	10.03

Employees	24,535	LT Debt/Eq	0.47	Earnings	Mar 04	SMA200	2.39%	Avg Volume	9.98M	Price	9.93

IPO Date	Jul 25, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	-56.58% -50.36%	Net Debt/EBITDA	2.59	Volume	5,493,396	Change	-1.05%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jan-23-26	Upgrade	Barclays	Equal Weight → Overweight
Sep-16-25	Downgrade	Barclays	Overweight → Equal Weight
Jan-10-25	Reiterated	Morgan Stanley	Overweight	$9.15 → $10
Apr-08-24	Reiterated	Morgan Stanley		$9.15
Apr-06-23	Upgrade	Argus Research	Hold → Buy

Latest News

Aug-05-26

Aug-05-2612:00PM

Haleon plc (HLN) Q2 2026 Earnings Call Prepared Remarks TranscriptSeekingAlpha

Aug-04-26

Aug-04-2612:41PM

ACCO vs. HLN: Which Stock Is the Better Value Option?zacks.com

Jul-30-26

Jul-30-2607:38AM

Haleon slides as quality of growth questionedproactiveinvestors.com

07:07AM

Haleon plc (HLN) Q2 2026 Earnings Call Transcriptseekingalpha.com

Jul-29-26

Jul-29-2605:39AM

18 Ideal 'Safer' Buyable July Dogs Emerge After 10 Years Of DiggingSeekingAlpha

Jul-28-26

Jul-28-2603:15AM

Bank of New York Mellon Corp Has $25.99 Million Stock Position in Haleon PLC Sponsored ADR $HLNdefenseworld.net

Jul-24-26

Jul-24-2604:07AM

FTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZenecainvezz.com

Jul-01-26

Jul-01-2612:40PM

LCUT vs. HLN: Which Stock Is the Better Value Option?zacks.com

11:54AM

Haleon Bets on Microsoft AI To Support Growth and Reach One Billion More Consumers by 2030benzinga.com

05:00AM

Haleon to Accelerate AI-powered Transformation With New Five-year Microsoft Collaborationbusinesswire.com

Jun-29-26

Jun-29-2608:30AM

Nasdaq leads Wall Street higher at the open as uneasy Iran truce holdsproactiveinvestors.com

05:51AM

Futura swaps Haleon for Market Performance Group to drive US Eroxon sales - UPDATEproactiveinvestors.com

Jun-26-26

Jun-26-2604:05PM

Unilever exploring $4 billion bid for Thorne supplementsYahoo

Jun-25-26

Jun-25-2612:41PM

Is Haleon plc (HLN) Stock Still a Growth Opportunity After Analyst Downgrade?Yahoo

Jun-15-26

Jun-15-2610:30AM

Haleon: Waiting For A Good Entry Point In Consumer Healthcare LeaderSeekingAlpha

Company

Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.

Ownership

Total institutional ownership12.68%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	14,905	14,561	14,354	—	—	—	—	—
Cost of Goods Sold Incl. D&A	5,135	5,059	5,475	—	—	—	—	—
Gross Profit	9,769	9,224	8,878	—	—	—	—	—
Selling, General and Administrative Excl. Other	5,888	5,761	5,537	—	—	—	—	—
Research and Development	414	407	381	—	—	—	—	—
Other Operating Expense	0	-321	141	—	—	—	—	—
Operating Income	3,468	3,184	2,819	—	—	—	—	—
Interest Expense	424	439	503	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-194	96	125	—	—	—	—	—
Net Income Before Taxes	2,851	2,841	2,441	—	—	—	—	—
Income Taxes	664	609	556	—	—	—	—	—
Consolidated Net Income	2,167	2,152	1,843	—	—	—	—	—
Net Income From Continuing Operations	2,186	2,169	1,885	—	—	—	—	—
Net Income	2,167	2,152	1,843	—	—	—	—	—
EPS (Recurring)	0.48	0.48	0.41	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	0.48	0.48	0.41	—	—	—	—	—
EPS (Diluted)	0.48	0.48	0.41	—	—	—	—	—
EBITDA	3,938	3,801	3,212	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	20.68	21.27	23.33	—	—	—	—	—
Price To Sales Ratio	2.96	3.11	3.03	—	—	—	—	—
Gross Margin	65.54	63.35	61.85	—	—	—	—	—
Operating Margin	23.27	21.87	19.64	—	—	—	—	—
Net Margin	14.54	14.78	12.84	—	—	—	—	—
Shares Outstanding	4,443	4,481	4,566	—	—	—	—	—
Market Capitalization	44,097	45,303	43,560	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.